viewClinigen Group PLC

Clinigen Group agrees cancer drug supply deal

The company said the agreement with US life sciences group Iovance Biotherapeutics offers the chance to "revitalise" its Proleukin product

Clinigen Group PLC -
Proleukin will be used in clinical trials aimed at creating a new cancer immunotherapies

Clinigen Group PLC (LON:CLIN) has taken a “first significant step” to revitalise its Proleukin drug by agreeing to supply the product to an American life sciences company developing exciting new cancer immunotherapies.

Iovance Biotherapeutics is carrying out pivotal studies of its tumour infiltrating lymphocytes (TIL) technology on head, neck and lung patients with advanced forms of the killer disease.

Proleukin, currently used to treat liver and skin cancer, is part of the TIL therapy treatment regimen being assessed.

As such, it will be made available by Clinigen in bulk supply over a two-year period so Iovance has uninterrupted access for its clinical trials.

Chief executive Shaun Chilton said: “Proleukin is the only approved IL-2 in the US and Europe that is currently being used in TIL therapy development and is an inherent component of these programs. This is a product that is involved in over 80 clinical trials in the US alone, which presents other similar opportunities for us to pursue.”

Quick facts: Clinigen Group PLC

Price: 980.5 GBX

Market: AIM
Market Cap: £1.3 billion


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Clinigen Group PLC named herein, including the promotion by the Company of Clinigen Group PLC in any Content on the Site, the Company receives...



Clinigen Group reports on 'transformational' year with strong profit growth

Clinigen Group PLC's (LON:CLIN) head of investor relations Matt Parrish caught up with Proactive London's Andrew Scott following the release of the firm's results for the year to June 2019. The firm's gross profit was up 30% at £182.3mln, while revenues were ahead 20% at £456.9mln. Underlying...

on 19/9/19

2 min read